Committee flags questions about biomarker and genetic testing bill; members raise insurance and privacy concerns

The Health Care committee discussed H.136 and the broader topic of biomarkers and genetic testing during its May 9 meeting, exploring both clinical benefits and potential policy risks.

Members said biomarkers could speed diagnosis for conditions such as certain autoimmune disorders, long COVID and hereditary risks, and that clinicians described examples where genetic information might change treatment. At the same time several members voiced concern about how insurers might use genetic information and about potential discrimination or coverage denial.

Committee members asked to schedule testimony to understand the bill’s scope and to hear from clinicians and patient advocates. Participants noted specific clinical examples discussed in the meeting, including genetic predispositions such as MTHFR mutations and the possible value of preemptive clinical interventions (for example, treating blood‑clot risk during COVID infection in people with certain genetic dispositions).

The group also raised procedural concerns: members requested clear explanations of what the bill would and would not require and how it would interact with existing insurance rules. Multiple members said they wanted more information on how biomarker testing would affect coverage decisions, privacy protections and whether federal or state law limits insurer use of genetic data.

Members asked staff to line up experts (clinicians, patient advocates, and privacy specialists) for a structured, evidence‑based hearing that would include examples of how biomarker results would change clinical care and the safeguards needed to protect patients. The committee did not take action on H.136 at the meeting.